PortfoliosLab logoPortfoliosLab logo
NTLA vs. SE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NTLA vs. SE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intellia Therapeutics, Inc. (NTLA) and Sea Limited (SE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NTLA achieves a 64.07% return, which is significantly higher than SE's -27.81% return.


NTLA

1D
13.29%
1M
10.82%
YTD
64.07%
6M
51.44%
1Y
92.31%
3Y*
-29.03%
5Y*
-27.22%
10Y*
-6.63%

SE

1D
2.94%
1M
9.01%
YTD
-27.81%
6M
-31.99%
1Y
-45.24%
3Y*
16.26%
5Y*
-18.55%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

NTLA vs. SE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NTLA
Intellia Therapeutics, Inc.
64.07%-22.90%-61.76%-12.61%-70.49%117.35%270.82%7.47%-28.98%-31.89%
SE
Sea Limited
-27.81%20.24%161.98%-22.16%-76.74%12.39%394.90%255.30%-15.08%-18.02%

Correlation

The correlation between NTLA and SE is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.18

Correlation (3Y)
Calculated over the trailing 3-year period

0.21

Correlation (5Y)
Calculated over the trailing 5-year period

0.35

Correlation (All Time)
Calculated using the full available price history since Oct 23, 2017

0.34

The correlation between NTLA and SE shifts across timeframes, from 0.18 (1 year) to 0.35 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

NTLA:

$1.75B

SE:

$58.59B

EPS

NTLA:

-$3.58

SE:

$2.57

PS Ratio

NTLA:

24.59

SE:

2.29

PB Ratio

NTLA:

2.81

SE:

4.56

Total Revenue (TTM)

NTLA:

$66.09M

SE:

$25.19B

Gross Profit (TTM)

NTLA:

-$33.92M

SE:

$11.15B

EBITDA (TTM)

NTLA:

-$299.32M

SE:

$2.33B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NTLA vs. SE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NTLA
NTLA Risk / Return Rank: 6868
Overall Rank
NTLA Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
NTLA Sortino Ratio Rank: 7070
Sortino Ratio Rank
NTLA Omega Ratio Rank: 7474
Omega Ratio Rank
NTLA Calmar Ratio Rank: 6666
Calmar Ratio Rank
NTLA Martin Ratio Rank: 6161
Martin Ratio Rank

SE
SE Risk / Return Rank: 1010
Overall Rank
SE Sharpe Ratio Rank: 77
Sharpe Ratio Rank
SE Sortino Ratio Rank: 77
Sortino Ratio Rank
SE Omega Ratio Rank: 99
Omega Ratio Rank
SE Calmar Ratio Rank: 1414
Calmar Ratio Rank
SE Martin Ratio Rank: 1313
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NTLA vs. SE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Sea Limited (SE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


NTLASEDifference
Sharpe ratioReturn per unit of total volatility

+1.87

Sortino ratioReturn per unit of downside risk

+3.04

Omega ratioGain probability vs. loss probability

1.25

0.84

+0.41

Calmar ratioReturn relative to maximum drawdown

1.30

-0.75

+2.06

Martin ratioReturn relative to average drawdown

2.06

-1.27

+3.33

NTLA vs. SE - Sharpe Ratio Comparison

The current NTLA Sharpe Ratio is 0.97, which is higher than the SE Sharpe Ratio of -0.90. The chart below compares the historical Sharpe Ratios of NTLA and SE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


NTLASEDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.97

-0.90

+1.87

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.34

-0.29

-0.05

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.08

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.05

0.36

-0.41

Drawdowns

NTLA vs. SE - Drawdown Comparison

The maximum NTLA drawdown since its inception was -96.45%, which is greater than SE's maximum drawdown of -90.51%. Use the drawdown chart below to compare losses from any high point for NTLA and SE.


Loading charts...

Drawdown Indicators


NTLASEDifference

Max Drawdown

Largest peak-to-trough decline

-96.45%

-90.51%

-5.94%

Max Drawdown (1Y)

Largest decline over 1 year

-71.27%

-60.22%

-11.05%

Max Drawdown (3Y)

Largest decline over 3 years

-86.36%

-60.22%

-26.14%

Max Drawdown (5Y)

Largest decline over 5 years

-96.45%

-90.51%

-5.94%

Max Drawdown (10Y)

Largest decline over 10 years

-96.45%

Current Drawdown

Current decline from peak

-91.66%

-74.91%

-16.75%

Average Drawdown

Average peak-to-trough decline

-57.05%

-44.03%

-13.02%

Ulcer Index

Depth and duration of drawdowns from previous peaks

45.02%

35.62%

+9.40%

Volatility

NTLA vs. SE - Volatility Comparison

Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 22.22% compared to Sea Limited (SE) at 18.95%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than SE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NTLASEDifference

Volatility (1M)

Calculated over the trailing 1-month period

22.22%

18.95%

+3.27%

Volatility (6M)

Calculated over the trailing 6-month period

54.98%

37.49%

+17.49%

Volatility (1Y)

Calculated over the trailing 1-year period

96.16%

50.36%

+45.80%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

80.84%

64.07%

+16.77%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

78.35%

62.62%

+15.73%

Dividends

NTLA vs. SE - Dividend Comparison

Neither NTLA nor SE has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

NTLA vs. SE - Financials Comparison

This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Sea Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B20222023202420252026
15.05M
7.10B
(NTLA) Total Revenue
(SE) Total Revenue
Values in USD except per share items

Frequently Asked Questions


NTLA and SE have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NTLA has higher volatility (22.22%) compared to SE (18.95%). In terms of maximum drawdown, NTLA dropped -96.45% vs SE's -90.51%.

NTLA currently has the higher Sharpe Ratio (0.97 vs -0.90), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NTLA and SE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer